SER - NYSE
Serina Therapeutics, Inc.
$5.00
+0.0000%Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
At a Glance
Live Snapshotser
Total Current Liabilities
Last Annual Value
2.37M
3-Year CAGR
85%
5-Year CAGR
-6%
10-Year CAGR
-21%
Serina Therapeutics, Inc. Competitors Analysis of Total Current Liabilities
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Serina Therapeutics, Inc. NYSE:SER | 2.37M | -26.3% | 44.8% | -21.2% | |
 Mersana Therapeutics, Inc. NASDAQ:MRSN | 62.46M | -0.6% | 5.6% | 8.2% | |
 Coeptis Therapeutics, Inc. NASDAQ:COEP | 1.77M | -16.1% | -8.6% | N/A | |
 Estrella Immunopharma, Inc. NASDAQ:ESLA | 13.54M | 321.6% | 70.3% | N/A | |
 Fortress Biotech, Inc. NASDAQ:FBIO | 49.74M | -16.3% | -13.2% | -1.3% | |
 Karyopharm Therapeutics Inc. NASDAQ:KPTI | 92.06M | 9.8% | 4.5% | 18.8% | |
 Senti Biosciences, Inc. NASDAQ:SNTI | 13.15M | 1.2% | -2.0% | N/A | |
 Telomir Pharmaceuticals, Inc. Common Stock NASDAQ:TELO | 1.43M | 2.3% | 59.5% | N/A |
Serina Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your SER research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.